Europe approves Lilly's diabetes drug

The European regulatory body has approved Eli Lilly’s Trulicity, its drug against type 2 diabetes

approved-29149-1280

The marketing authorisation is based primarily on six large Phase III trials

Eli Lily has announced that the European Commission (EU) has granted marketing approval to its injectable once-weekly Trulicity treatment for adults with type 2 diabetes.

Trulicity is a GLP-1 receptor agonists. The marketing authorisation is based primarily on six large Phase III trials and in the first five, Trulicity 1.5mg was superior to placebo and four commonly used type 2 diabetes medicines in reducing average blood sugar levels.

The drug can be taken any time of a day, with or without meals, and either by itself or with other treatments for the most common form of diabetes.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X